Personalized Cancer Vaccines Tested

Interesting LATimes article describes tests underway by startup Genitope, which is attempting to bring to market a vaccine for non-Hodgkins lymphoma. The MyVax vaccine is fine-tuned to each patient's specific cancer strain, and Genitope has developed a way to identify and produce the needed vaccine within six months.

The goal is to produce lifelong remissions in as many patients as possible.

Biovest is another company seeking approval of a cancer-fighting vaccine.